Hospital

Investigators in a clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months to under 5 years noted that their research will continue with new changes.

Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.

The treatment was first approved in 2013 for adults as a 1500 mg course of treatment, administered as 2 doses of 750 mg each separated by at least 7 days.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity, addresses disparities occurring in diabetes care among racial and ethnic populations.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses the scope and focus of the work of NIH ORWH.

A panel of experts discuss the future of psychedelic medicine and the role of the pharmacy in that future.

Cutaquig was recently approved for the treatment of pediatric patients aged 2 years and older with primary humoral immunodeficiency.

Study may help guide COVID-19 vaccination strategies for patients with blood disorders.

Trial seeks to provide high-level evidence for improving the initial treatment for acute Kawasaki disease.

A single booster dose of the GlaxoSmithKline and Sanofi recombinant adjuvanted COVID-19 vaccine candidate delivered consistent and strong immune responses.

Up to 60% of arteriovenous fistulas fail to develop properly due to smooth muscle cell hyperplasia.

This trial is the first to assess the use of isatuximab as a first-line treatment for newly diagnosed, transplant-eligible patients up to 70 years of age, according to the study authors.

Patients with hormone receptor-positive breast cancer doubled their median progression-free survival following a switch to fulvestrant plus palbociclib.

Patients with breast cancer treated with pyrotinib plus capecitabine had a 31% lower risk of death than those treated with lapatinib and capecitabine

New technology provides information on the benefit of adding atezolizumab to chemotherapy as a neoadjuvant treatment for patients with early high-risk and locally advanced triple-negative breast cancer.

Zofran aids in the prevention of nausea and vomiting.

Experts reviewed the efficacy and safety of the recommended treatment regimens and discussed which treatment strategy they would recommend for their patients.

NRx Pharmaceuticals announces that no new concerns were identified by an independent data safety monitoring board, which recommends continued enrollment.

However, active disease alone for hospitalized patients was not associated with greater odds of dying from COVID-19, nor was receiving ongoing cancer treatment.

Uterine cancers that developed in patients with breast cancer treated with tamoxifen had fewer phosphoinositol-3-kinase (PI3K) pathway mutations and may have been driven by tamoxifen-induced PI3K pathway activation.

Data from a couple of new molecules could be encouraging for the treatment of acute myeloid leukemia and diffuse large B-cell lymphoma

The findings are consistent with an interim analysis showing that the drug significantly reduced the risk of hospitalization or death for any cause by 89% compared with the placebo.

Since its initial approval in 2016 for urothelial carcinoma, atezolizumab has received FDA approval for an additional 5 types of carcinomas.

Technology, COVID-19, and scope expansion—here’s how pharmacists can capitalize on opportunities coming in the new year.

Serotypes 22F, 33F, and 3 represent more than a quarter of invasive pneumococcal disease in children under the age of 5

Offering individual advice and counseling to patients can help combat the risks of driving under the influence of prescription drugs.

In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients